APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July17, 2017, the compensation committee of our board of directors approved bonus payments for fiscal year 2017 and salary changes for fiscal year 2018 for Susan Washer, our president and chief executive officer, Mark Shearman, our chief scientific officer, Stephen Potter, our vice president and chief business officer, Michael Goldstein, our chief medical officer and Jeffrey Chulay, our executive director of clinical strategy and former chief medical officer.The following table sets forth for each individual the amount of their bonus for fiscal year 2017 and their salary for fiscal year 2018.

About APPLIED GENETIC TECHNOLOGIES CORPORATION (NASDAQ:AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).